Significant correlation between salivary and serum Ca 15-3 in healthy women and breast cancer patients

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 11, 2014, Pages 4659-4662

  Laidi, Fatna ^a   Bouziane, Amal ^a   Lakhdar, Amina ^b   Khabouze, Samira ^b   Amrani, Mariam ^c   Rhrab, Brahim ^b   Zaoui, Fatima ^a  

^a MOHAMMED V UNIVERSITY IN RABAT   (Morocco)

^b IBN SINA HOSPITAL   (Morocco)

^c NATIONAL INSTITUTE OF ONCOLOGY   (Morocco)

Author keywords

Breast cancer; CA 15 3; Diagnostic approaches; Saliva; Serum; Tumor markers

Indexed keywords

MUCIN 1; TUMOR MARKER;

ADULT; BLOOD; BREAST TUMOR; CASE CONTROL STUDY; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; MOROCCO; SALIVA; WOMEN'S HEALTH;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MIDDLE AGED; MOROCCO; MUCIN-1; SALIVA; TUMOR MARKERS, BIOLOGICAL; WOMEN'S HEALTH;

EID: 84903737947     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.11.4659     Document Type: Article

References (27)

1. Agha-Hosseini F, Mirzaii-Dizgah I, Rahimi A (2009). Correlation of serum and salivary CA15-3 levels in patients with breast cancer. Medicina Oral S, 10, 521-4.
2. Atoum M, Nimer N, Abdeldayem S, et al (2012). Relationships among serum CA15-3 tumor marker, tnm staging, and estrogen and progesterone receptor expression in benign and malignant breast lesions. Asian Pac J Cancer Prev, 13, 857-60.
3. Begum M, Karim S, Malik A, et al (2012). CA 15-3 (mucin-1) and physiological characteristics of breast cancer from Lahore, Pakistan. Asian Pac J Cancer Prev, 13, 5257-61.
4. Bigler LR, Streckfus CF, Copeland L, et al (2002). The potential use of saliva to detect recurrence of disease in women with breast carcinoma. J Oral Pathol Med, 31, 421-31.
5. Clinton SR, Beason KL, Bryant S, et al (2003). A comparative study of four serological tumor markers for the detection of breast cancer. Biomed Sci Instrum, 39, 408-14.
6. Colomer R, Ruibal A, Salvador L (1989). Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer, 64, 1674-81.
7. Dilhuydy M-H (2009). Imagerie au service du depistage : l'exemple du depistage organise du cancer du sein. Bull Cancer, 96, 1071-86.
8. Frenette PS, Thirlwell MP, Trudeau M, et al (1994) The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies. Tumour Biol, 15, 247-54.
9. Hofman L F (2001). Human Saliva as a Diagnostic Specimen. J Nutr, 131, 1621-5.
10. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
11. Lac G (1998). Interêt et champs d'application des dosages salivaires. Science & Sports, 13, 55-63.
12. Mandel ID (1993). Salivary diagnosis: promises, promises. Ann N Y Acad Sci, 694, 1-10.
13. Maric P, Ozretic P, Levanat S, et al (2011). Tumor Markers in Breast Cancer-Evaluation of their Clinical Usefulness. Coll Antropol, 35, 241-7.
14. Mcintyre R, Bigler L, Dellinger T, et al (1999). Oral contraceptive usage and the expression of CA 15-3 and c-erbB-2 in the saliva of healthy women. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 88, 687-90.
15. Moazzezy N, Farahany T-Z, Oloomi M, et al (2014). Relationship between preoperative serum CA15-3 and CEA levels and clinicopathological parameters in breast cancer. Asian Pac J Cancer Prev, 15, 1685-8.
16. Navazesh M, Christensen CM (1982). A comparison of whole mouth resting and stimulated salivary measurement procedures. J Dent Res, 61, 1158-62.
17. Navazesh M (1993). Methods for collecting saliva. Ann N Y Acad Sci, 694, 72-7.
18. Nicolini A, Carpi A, Ferrari P, et al (2008). Immunotherapy prolongs the serum CEA-TPA-CA15.3 lead time at the metastatic progression in endocrine-dependent breast cancer patients: a retrospective longitudinal study. Cancer Lett, 263, 122-9.
19. Porika M, Malotu N, Veldandi U-K, et al (2010). Evaluation of tumor markers in Southern Indian breast cancer patients. Asian Pac J Cancer Prev, 11, 157-9.
20. Ray A (2012). Adipokine leptin in obesity-related pathology off breast cancer. J Biosci, 37, 289-94.
21. Streckfus C, Bigler L (2005). The use of soluble, salivary c-erbB-2 for the detection and post-operative follow-up of breast cancer in women: the results of a five-year translational research study. Adv Dent Res, 18, 17-24.
22. Streckfus C, Bigler L, Dellinger T, et al (1999). CA 15-3 and c-erbB-2 presence in the saliva of women. Clin Oral Investig, 3, 138-43.
23. Tarhan M-O, Gonel A, Kucukzeybek Y, et al (2013). Prognostic significance of circulating tumor cells and serum ca15-3 levels in metastatic breast cancer, single center experience, preliminary results. Asian Pac J Cancer Prev, 14, 1725-9.
24. Tjemslanda L, Soreide JA (2004). Operable breast cancer patients with diagnostic delay oncological and emotional characteristics. Eur J Surg Oncol, 30, 721-7.
25. Toth B, Nieuwland R, Liebhardt S, et al (2008). Circulating microparticles in breast cancer patients: a comparative analysis with established biomarkers. Anticancer Res, 28, 1107-12.
26. Xiaoqiang Tang (2013). Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. Cancer Lett, 332, 3-10.
27. Zhang S-J, Hu Y, Qian H-L, et al (2013). Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer. Asian Pac J Cancer Prev, 14, 3937-40.